Rheumatic Diseases Overview

Principles

Definition

Rheumatic diseases is a broad category within medicine and an active field of research focused on conditions that primarily affect the body's connective tissues, particularly the joints, muscles, and bones. These conditions are often characterized by inflammation, autoimmunity, and chronic pain. As an academic concept, it encompasses the study of their complex pathophysiology, diverse clinical manifestations, epidemiology, diagnostic approaches, and therapeutic strategies, holding significant importance due to the substantial morbidity, disability, and socioeconomic burden these disorders impose globally.

Ontological type

Pathophysiology

Therapeutic Strategies

Diagnostic Approaches

Key developments

Key Figures

Systemic Conceptualization and Control era

Philip S. Hench, Edward C. Kendall, and Tadeusz Reichstein reframed rheumatic diseases as systemic disorders by introducing cortisone and related glucocorticoids, establishing pharmacologic control over systemic inflammation. This corticosteroid revolution provided the first reproducible anti-inflammatory tools for diseases such as rheumatoid arthritis and propelled a systemic management approach. Concurrently, Erik Waaler identified the rheumatoid factor in 1940, while Tillet and Garner described C-reactive protein as a serum biomarker, embedding serology into systemic disease monitoring. Together, these insights from rheumatology, serology, and cross-disciplinary sources including nutrition, infection, vascular factors, and epidemiology underpinned mechanism-based strategies and systemic concepts that guided subsequent research.

Standardization and Mechanistic Frameworks era

Frank C. Arnett [1] was affiliated with Stanford University [3] and Johns Hopkins University [4] during this era. His key contribution was the Revised Criteria for the Classification of Rheumatoid Arthritis [7], which established standardized diagnostic criteria enabling reproducible phenotyping for epidemiology and trials and thereby advancing mechanistic investigations in rheumatology. Eng M. Tan [2] was associated with the University of California, San Francisco [5] and Baylor College of Medicine [6] during this era. His pivotal work, Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA) [8], helped anchor autoantibody profiling as a mechanistic tool and catalyzed investigations into immunogenetics.

Precision-Targeted Biologic Therapies era

Peter A. Merkel [1] is a leading rheumatologist associated with Harvard University [3] and the University of California, San Francisco [4] in this era of precision-targeted biologic therapies. His key contribution in this era is shaping the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides [5], which standardized terminology and classification to enable consistent diagnosis, phenotyping, and comparability across studies crucial for precision rheumatology. David Jayne [2] is also associated with Harvard University [3] and the University of California, San Francisco [4], contributing to this era through involvement in the CHCCN nomenclature [5]. This standardization supports cross-study integration, guideline development, and targeted biologic strategies in rheumatic diseases, as underscored by the CHCCN nomenclature work [5].